Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome

REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
April 02, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
February 20, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome

Minutes Confirm Alignment on Soleno’s Planned Phase III Clinical Trial Soleno In Process of Initiating Phase III Study REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics,...
December 12, 2017 08:30 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces $15 Million Private Placement

Financing to Support Planned Phase III Clinical Program for DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a...
December 08, 2017 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology

REDWOOD CITY, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
November 22, 2017 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
November 14, 2017 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results

Completed Successful EMA Meeting for DCCR in Prader-Willi SyndromeContinued Preparations to Begin Phase III ProgramPresented Positive Updated Safety and Efficacy Data from Pilot Clinical Trial of DCCR...
October 23, 2017 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements

REDWOOD CITY, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
October 12, 2017 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
October 11, 2017 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...